{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:40:34Z","timestamp":1733157634969,"version":"3.30.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3165,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Excess hepatic iron is known to enhance both porphyria cutanea tarda (PCT) and experimental uroporphyria. Since previous studies have suggested a role for ascorbate (AA) in suppressing uroporphyria in AA-requiring rats (in the absence of excess iron), the present study investigated whether AA could suppress uroporphyria produced by excess hepatic iron. Hepatic URO accumulation was produced in AA-requiring<\/jats:bold>\n                                 <jats:bold>\n                                    Gulo\n                                 <\/jats:bold>\n                                 <jats:bold>(\u2212\/\u2212) mice by treatment with 3,3\u2032,4,4\u2032,5-pentachlorbiphenyl, an inducer of CYP1A2, and 5-aminolevulinic acid. Mice were administered either sufficient AA (1000 ppm) in the drinking water to maintain near normal hepatic AA levels or a lower intake (75 ppm) that resulted in 70 % lower hepatic AA levels. The higher AA intake suppressed hepatic URO accumulation in the absence of administered iron, but not when iron dextran (300\u2013500 mg Fe\/kg) was administered. This effect of iron was not due to hepatic AA depletion since hepatic AA content was not decreased. The effect of iron to prevent AA suppression of hepatic URO accumulation was not observed until a high hepatic iron threshold was exceeded. At both low and high AA intakes, hepatic malondialdehyde (MDA), an indicator of oxidative stress, was increased three-fold by high doses of iron dextran. MDA was considerably increased even at low iron dextran doses, but without any increase in URO accumulation. The level of hepatic CYP1A2 was unaffected by either AA intake.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>: In this mouse model of PCT, AA suppresses hepatic URO accumulation at low, but not high hepatic iron levels. These results may have implications for the management of PCT. (Hepatology 2007;45:187\u2013194.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21474","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T23:03:15Z","timestamp":1166828595000},"page":"187-194","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda"],"prefix":"10.1097","volume":"45","author":[{"given":"Nadia","family":"Gorman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Zaharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi S.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana G.","family":"Szakacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith M.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Balestra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline F.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-24-20241202","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1046\/j.1523-1747.2000.00148.x","article-title":"Coinheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda.","volume":"115","author":"Brady","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R3-24-20241202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004280100401","article-title":"C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients.","volume":"439","author":"Tannapfel","year":"2001","journal-title":"Virchows Arch"},{"key":"R4-24-20241202","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1013746828074","article-title":"Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.","volume":"47","author":"Egger","year":"2002","journal-title":"Dig Dis Sci"},{"key":"R5-24-20241202","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/bj3300149","article-title":"Uroporphyria produced in mice by iron and 5aminolaevulinic acid does not occur in Cyp1a2() null mutant mice.","volume":"330","author":"Sinclair","year":"1998","journal-title":"Biochem J"},{"key":"R7-24-20241202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1006\/abbi.1993.1376","article-title":"Ascorbic acid inhibition of cytochrome P450catalyzed uroporphyrin accumulation.","volume":"304","author":"Sinclair","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"R8-24-20241202","first-page":"565","article-title":"Ascorbic acid inhibits chemically induced uroporphyria in ascorbaterequiring rats.","volume":"22","author":"Sinclair","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R9-24-20241202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0022-2143(97)90096-2","article-title":"Ascorbic acid deficiency in porphyria cutanea tarda.","volume":"130","author":"Sinclair","year":"1997","journal-title":"J Lab Clin Med"},{"key":"R10-24-20241202","first-page":"185","article-title":"Ascorbate status of patients with porphyria cutanea tarda symptomatica and its effect on porphyrin metabolism.","volume":"40","author":"Percy","year":"1975","journal-title":"S Afr J Med Sci"},{"key":"R11-24-20241202","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1073\/pnas.97.2.841","article-title":"Aortic wall damage in mice unable to synthesize ascorbic acid.","volume":"97","author":"Maeda","year":"2000","journal-title":"Proc Natl Acad Sce U S A"},{"key":"R12-24-20241202","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-9258(18)65809-0","article-title":"The occurrence and determination of deltaaminolevulinic acid and porphobilinogen in urine.","volume":"219","author":"Mauzerall","year":"1956","journal-title":"J Biol Chem"},{"key":"R13-24-20241202","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/bj2690437","article-title":"Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P450mediated uroporphyrinogen oxidation.","volume":"269","author":"Lambrecht","year":"1990","journal-title":"Biochem J"},{"key":"R14-24-20241202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj2220737","article-title":"Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Essential role for induction of cytochrome P448.","volume":"222","author":"Sinclair","year":"1984","journal-title":"Biochem J"},{"key":"R15-24-20241202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent.","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"R16-24-20241202","first-page":"779","article-title":"Identification of CYP1A5 as the CYP1A enzyme mainly responsible for uroporphyrinogen oxidation induced by Ah receptor ligands in chicken liver and kidney.","volume":"25","author":"Sinclair","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"R17-24-20241202","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1053\/jhep.2001.21409","article-title":"Uroporphyria in Hfe mutant mice given 5aminolevulinate: A new model of Femediated porphyria cutanea tarda.","volume":"33","author":"Sinclair","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R18-24-20241202","first-page":"597","article-title":"Tinmesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: in vivo and in vitro studies.","volume":"46","author":"Wagner","year":"2000","journal-title":"Cell Mol Biol"},{"key":"R19-24-20241202","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/carcin\/12.9.1733","article-title":"Ascorbate is the principal reductant of chromium (IV) in rat liver and kidney ultrafiltrates.","volume":"12","author":"Standeven","year":"1991","journal-title":"Carcinogenesis"},{"key":"R20-24-20241202","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/jhep.2002.32487","article-title":"Uroporphyria in mice: Thresholds for hepatic CYP1A2 and iron.","volume":"35","author":"Gorman","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R21-24-20241202","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1079\/BJN19710101","article-title":"The effect of siderosis and ascorbic acid depletion on bone metabolism, with special reference to osteoporosis in the Bantu.","volume":"25","author":"Wapnick","year":"1971","journal-title":"Br J Nutr"},{"key":"R22-24-20241202","doi-asserted-by":"crossref","first-page":"E1406","DOI":"10.1152\/ajpendo.2000.279.6.E1406","article-title":"Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload.","volume":"279","author":"Chen","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R23-24-20241202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1024\/0300-9831.69.2.67","article-title":"Highdose vitamin C: a risk for persons with high iron stores?","volume":"69","author":"Gerster","year":"1999","journal-title":"Int J Vitam Nutr Res"},{"key":"R24-24-20241202","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1096\/fasebj.13.9.1007","article-title":"Does vitamin C act as a prooxidant under physiological conditions?","volume":"13","author":"Carr","year":"1999","journal-title":"FASEB J"},{"key":"R25-24-20241202","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/ajcn\/81.4.736","article-title":"Vitamins E and C are safe across a broad range of intakes.","volume":"81","author":"Hathcock","year":"2005","journal-title":"Am J Clin Nutr"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21474","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:07:21Z","timestamp":1733155641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21474","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}